<DOC>
	<DOCNO>NCT00080262</DOCNO>
	<brief_summary>The purpose research study assess response rate investigational drug BMS-247550 ( Ixabepilone ) woman metastatic breast cancer refractory anthracycline , taxane , capecitabine .</brief_summary>
	<brief_title>Novel Epothilone ( BMS-247550 ) Patients With Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients must receive 3 drug anthracycline , taxane , capecitabine ( alone combination ) resistant No 3 prior chemotherapy regimen metastatic set Must least one target lesion radiographically measurable Good performance status No history current brain leptomeningeal disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>